|
Myeloid Neoplasia
Citations 71-80 of 176 total displayed.
|
Past content
(since Jan 2009):
|
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
- Tiziano Barbui, Alessandra Carobbio, Alessandro Rambaldi, and Guido Finazzi
Blood 2009; 114: 759-763.
[Abstract]
[Full text]
[PDF]
Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10–positive leukemias
- Yi-Hui Lin, Purvi M. Kakadia, Ying Chen, Ya-Qiang Li, Aniruddha J. Deshpande, Christian Buske, Kang-Ling Zhang, Yi Zhang, Guo-Liang Xu, and Stefan K. Bohlander
Blood 2009; 114: 651-658.
[Abstract]
[Full text]
[PDF]
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
- Annelies G. Renner, Cédric Dos Santos, Christian Recher, Christian Bailly, Laurent Créancier, Anna Kruczynski, Bernard Payrastre, and Stéphane Manenti
Blood 2009; 114: 659-662.
[Abstract]
[Full text]
[PDF]
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin
- Sarit Assouline, Biljana Culjkovic, Eftihia Cocolakis, Caroline Rousseau, Nathalie Beslu, Abdellatif Amri, Stephen Caplan, Brian Leber, Denis-Claude Roy, Wilson H. Miller, Jr, and Katherine L. B. Borden
Blood 2009; 114: 257-260.
[Abstract]
[Full text]
[PDF]
Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
- Alfonso Quintás-Cardama, Xin Han, Hagop Kantarjian, and Jorge Cortes
Blood 2009; 114: 261-263.
[Abstract]
[Full text]
[PDF]
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- Omar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, Guillermo Garcia-Manero, Jay Patel, Martha Wadleigh, Sebastien Malinge, JinJuan Yao, Outi Kilpivaara, Rukhmi Bhat, Kety Huberman, Sabrena Thomas, Igor Dolgalev, Adriana Heguy, Elisabeth Paietta, Michelle M. Le Beau, Miloslav Beran, Martin S. Tallman, Benjamin L. Ebert, Hagop M. Kantarjian, Richard M. Stone, D. Gary Gilliland, John D. Crispino, and Ross L. Levine
Blood 2009; 114: 144-147.
[Abstract]
[Full text]
[PDF]
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
- Carlos M. Santamaría, María C. Chillón, Ramón García-Sanz, Cristina Pérez, María D. Caballero, Fernando Ramos, Alfonso García de Coca, José M. Alonso, Pilar Giraldo, Teresa Bernal, José A. Queizán, Juan N. Rodriguez, Pascual Fernández-Abellán, Abelardo Bárez, María J. Peñarrubia, Ana Balanzategui, María B. Vidriales, María E. Sarasquete, Miguel Alcoceba, Joaquín Díaz-Mediavilla, Jesús F. San Miguel, and Marcos Gonzalez
Blood 2009; 114: 148-152.
[Abstract]
[Full text]
[PDF]
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
- Azra Raza, Naomi Galili, Scott Smith, John Godwin, Jeffrey Lancet, Magda Melchert, Marsha Jones, James G. Keck, Lisa Meng, Gail L. Brown, and Alan List
Blood 2009; 113: 6533-6540.
[Abstract]
[Full text]
[PDF]
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
- Ulrich Keilholz, Anne Letsch, Antonia Busse, Anne Marie Asemissen, Sandra Bauer, Igor Wolfgang Blau, Wolf-Karsten Hofmann, Lutz Uharek, Eckhard Thiel, and Carmen Scheibenbogen
Blood 2009; 113: 6541-6548.
[Abstract]
[Full text]
[PDF]
Cancer in dyskeratosis congenita
- Blanche P. Alter, Neelam Giri, Sharon A. Savage, and Philip S. Rosenberg
Blood 2009; 113: 6549-6557.
[Abstract]
[Full text]
[PDF]
|
|
